Monica Tincopa is a Gastroenterology physician affiliated with University of California San Diego. OpenAlex indexes 110 publications with 1,528 citations (h-index 20).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
200 W Arbor Dr
San Diego, CA 921039000
Telephone
800-926-8273Provider last certified this registry record 18 Jul 2022.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Takeda Pharmaceuticals U.S.A., Inc.Program year20252 payments
- Novo Nordisk IncProgram year20251 payment
- Madrigal PharmaceuticalsProgram year20258 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
47.6%Loop diuretic21%Furosemide100%Part D<11 patientsBeta blocker15.3%Carvedilol100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
30.6%Bile Acid11.3%Ursodiol100%Part D<11 patientsProton pump inhibitor9.7%Omeprazole100%Part D<11 patients+ 1 more class in this area
Anti-infectives
12.1%Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor12.1%Entecavir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Head‐to‐Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of <scp>MetALD</scp> Versus <scp>MASLD</scp>: A Prospective Study
Alimentary Pharmacology & Therapeutics
2025 - Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease
Nature Reviews Gastroenterology & Hepatology
2025 - An Expert Consensus Delphi Panel in Metabolic Dysfunction- and Alcohol-associated Liver Disease: Opportunities and Challenges in Clinical Practice
Clinical Gastroenterology and Hepatology
2025 - Social Determinants of Health Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease Prevalence and Severity: A Systematic Review and Meta-Analysis
The American Journal of Gastroenterology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Jay Giedd, MD
University of California San Diego
Robert Weinreb, MD
University of California San Diego
Dilip Jeste, MD
University of California San Diego
Igor Grant, MD
University of California San Diego
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”